Evotec (ETR:EVT) Given a €42.00 Price Target by Morgan Stanley Analysts

Morgan Stanley set a €42.00 ($45.16) target price on Evotec (ETR:EVTGet Rating) in a report published on Friday morning, Borsen Zeitung reports.

A number of other equities analysts have also issued reports on EVT. Royal Bank of Canada set a €43.00 ($46.24) target price on shares of Evotec in a research report on Tuesday, April 12th. Warburg Research set a €43.00 ($46.24) target price on shares of Evotec in a research report on Friday, April 22nd. Berenberg Bank set a €47.00 ($50.54) target price on shares of Evotec in a research report on Wednesday, April 20th. Deutsche Bank Aktiengesellschaft set a €39.00 ($41.94) target price on shares of Evotec in a research report on Monday, February 7th. Finally, Jefferies Financial Group set a €55.00 ($59.14) target price on shares of Evotec in a research report on Wednesday, March 2nd.

ETR:EVT opened at €23.28 ($25.03) on Friday. The firm has a market cap of $4.12 billion and a PE ratio of 15.59. Evotec has a 12 month low of €22.93 ($24.66) and a 12 month high of €45.83 ($49.28). The company has a quick ratio of 2.22, a current ratio of 2.48 and a debt-to-equity ratio of 50.43. The company’s 50-day moving average price is €26.16 and its two-hundred day moving average price is €34.49.

About Evotec (Get Rating)

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health.

Featured Stories

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.